4768 Otsuka
- 2902.0
- -22.0-0.75%
Otsuka News
Jefferies Adjusts Otsuka Corporation's Price Target to 3,450 Yen From 3,925 Yen, Keeps at Buy
03:22 AM EDT, 06/13/2024 (MT Newswires) -- Jefferies Adjusts Otsuka Corporation's Price Target to 3,450 Yen From 3,925 Yen, Keeps at Buy
Loneliness deepens for American workers due to changes in the work style.
It seems that more and more Americans are experiencing deep loneliness in the workplace. While digital connections have increased, opportunities for direct human interaction have decreased. This way of working has been reported to deepen feelings of isolation. According to executives and researchers in the business world, the decrease in human connections in the workplace has led to increased resignations and absences, and loneliness has become a business challenge for many companies. <7962> King Jim <7972> Itoki <26>
Press Release: 2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner
2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner PR Newswire CHICAGO, June 2, 2024 CHICAGO, June 2, 2024 /PRNewswire/ -- 2Flo Venture
Correction: Otsuka Pharmaceutical's PTSD Treatment Candidate Sees Statistically Significant Results in Two Out of Three Trials
(Corrects headline and the story throughout to clarify that two out of three trials showed statistically significant results) Otsuka Holdings' (TYO:4578) subsidiary, Otsuka Pharmaceutical, reported th
Otsuka and Lundbeck Report Data From Three PTSD Treatment Trials
Otsuka Pharmaceutical's PTSD Treatment Candidate Fails to Meet Primary Endpoint in Phase 3 Trial
Otsuka Holdings' (TYO:4578) subsidiary, Otsuka Pharmaceutical, said a phase 3 clinical trial on its treatment candidate for post-traumatic stress disorder, or PTSD, failed to meet the primary endpoint
Selected for the first time as a "DX Spotlight Company" in 2024.
Solution provider Otsuka Corporation (located in Chiyoda-ku, Tokyo; President and Representative Director: Yuji Otsuka) has been selected as a "DX spotlight company for 2024" in the "Digital Transformation Stock (DX stock)" selected by the Ministry of Economy, Trade and Industry, the Tokyo Stock Exchange and the Independent Administrative Institution Information-technology Promotion Agency.＊ "DX stock" is a digital transformation (DX) that leads to improving corporate value from companies listed on the Tokyo Stock Exchange.
Nichibatalyst, Recruit HD, etc. (added) Rating
Upgrade-Bullish Code | Stock Name | Securities Company | Conventional | After Change |------|--------------|--------------|--------------|<7550＞|Zensho HD | Morgan S | “Equal W” | “Over W” | “Over W” | Downgrade-Bearish Code | Stock Name | Securities Company | Conventional | After the Change |----
Jefferies Adjusts Otsuka Holdings' Price Target to 7,800 Yen From 7,400 Yen, Keeps at Buy
05:02 AM EDT, 05/23/2024 (MT Newswires) -- Jefferies Adjusts Otsuka Holdings' Price Target to 7,800 Yen From 7,400 Yen, Keeps at Buy
Sharp, Sysmex, etc. (additional) Rating
Upgraded - Bullish Code | Stock Name | Securities Company | Conventional | After Change |------|----------|--------|--------|<9613＞|NTT DATA | City | “2” | “1” | Downgraded - Bearish Code | Stock Name | Securities Company | Conventional | After Change |------|------------
Otsuka Holdings' Attributable Profit Soars 26% in Fiscal Q1
Otsuka Holdings' (TYO:4578) profit attributable to owners of the parent soared 26% to 77.4 billion yen in the fiscal first quarter ended March 31, from 61.4 billion yen a year ago mainly due to increa
Esperion Therapeutics/Otsuka Partnered Cholesterol Drug Shows Effective In Japan Study
Monday, Esperion Therapeutics (NASDAQ:ESPR) and Otsuka Pharmaceutical Co Ltd announced that the primary endpoint in the Phase 3 trial in Japan for bempedoic acid for hypercholesterolemia was achieved.
Esperion, Otsuka Report Primary Endpoint Was Achieved In Phase 3 Trial In Japan For Bempedoic Acid As Potential Treatment For Patients With Hypercholesterolemia
The trial demonstrated statistically significant outcomes on the primary endpoint for bempedoic acid and highlighted its potential future value to patients in Japan.In the preliminary results, the per
Recor Medical Champions Global Action on World Hypertension Day: Early Intervention and Continued Innovation Crucial in Tackling This Silent Killer Impacting Billions Worldwide
FRANKFURT, GERMANY and PALO ALTO, Calif., May 17, 2024 /PRNewswire/ -- Hypertension, or high blood pressure, affects one in three Europeans over the age of 30 and more than one billion people worldwi
Recor Medical Soutient Des Actions Mondiales À L'occasion De La Journée Mondiale De L'hypertension : L'intervention Précoce Et L'innovation Continue Sont Les Clés De La Lutte Contre Ce Tueur Silencieux Qui Affecte Des Milliards De Personnes Dans...
Recor Medical Soutient Des Actions Mondiales À L'occasion De La Journée Mondiale De L'hypertension : L'intervention Précoce Et L'innovation Continue Sont Les Clés De La Lutte Contre Ce Tueur Silen
Otsuka: Confirmation
Otsuka: Quarterly Report - 64th Quarter (2024/01/01 - 2024/03/31)
Yunlou Stock List (Weekly Chart) [Ichimoku Equilibrium Chart/Cloud Stock List]
○Kumojo Owaru Stock List Market Code Stock Name Closing Price Advance Span A Advance Span B Tokyo Stock Exchange Prime ＜2201＞ Morinaga Confectionery 2642 2615.25 2337 ＜2281＞ Prima Ham 2390 2357.75 2293 ＜2440＞ Gurunavi 337 307.5 336.5 ＜2475＞ W
Otsuka America, Inc's. Data and Technology Company Will Support Rejoyn Commercialization & Personalized Patient Engagement
Otsuka Precision Health will continue advancing Otsuka's longstanding work in digital by delivering first-of-its-kind, evidence-based patient experience service to overcome common and overlooked barriers to care
List of Unrivaled Stocks (Part 2) [Ichimoku Equilibrium Chart/Kumoku Stock List]
○List of Unbroken Stocks Market Code Stock Name Closing Price Advance Span A Advance Span B Tokyo Stock Exchange Prime ＜1786＞ Oriental Shiraishi 376 391.25 378 ＜1871＞ PS Mitsubishi 992 1054 1004 ＜1925＞ Daiwa House 4407 4411 4460.5 ＜1946＞ Toe
Analysis
Price Target
No Data
